中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Decompressive Craniectomy In Malignant Middle Cerebral Artery Infarcts

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态已终止
赞助商
Assistance Publique - Hôpitaux de Paris

关键词

抽象

The purpose of this study is to determine if patients with malignant middle cerebral artery infarction have a better clinical outcome after early decompressive surgery compared to standard medical management.

描述

The Decompressive Craniectomy In MALignant middle cerebral artery infarction (DECIMAL) trial is a prospective, multicenter, randomized, open (single blind for the evaluation of the primary outcome measure) controlled study of the efficacy of decompressive craniectomy plus the standard medical therapy as compared with the standard medical therapy alone in patients with a malignant middle cerebral artery infarction. The study protocol is approved by a regional ethic committee (CCPPRB Hospital SAINT LOUIS, PARIS). The study is conducted in 13 stroke centers in France and is funded by the French Ministry of Health and the "ASSISTANCE PUBLIQUE- HOPITAUX DE PARIS". An independent Data Safety Monitoring Board (DSMB) monitors the safety, progress and ethics of the trial.

The aim of the trial is to determine if patients with malignant middle cerebral artery infarction have a better clinical outcome after early decompressive surgery compared to standard medical therapy alone.

Secondary objectives are to determine clinical or MRI based prognostic factors of better outcome after decompressive surgery.

日期

最后验证: 08/31/2007
首次提交: 09/12/2005
提交的预估入学人数: 09/12/2005
首次发布: 09/18/2005
上次提交的更新: 01/15/2008
最近更新发布: 01/16/2008
实际学习开始日期: 11/30/2001
预计主要完成日期: 04/30/2006
预计完成日期: 04/30/2006

状况或疾病

Malignant Middle Cerebral Artery Infarction

干预/治疗

Procedure: A

Procedure: A

相 3

手臂组

干预/治疗
Experimental: A
HEMICRANIECTOMY
Procedure: A
Decompressive hemicraniectomy and duraplasty

资格标准

有资格学习的年龄 18 Years 至 18 Years
有资格学习的性别All
接受健康志愿者
标准

Inclusion Criteria:

- Clinical and CT scan signs of complete infarction of the middle cerebral artery

- Onset of symptoms < 30 hours to a possible surgical intervention (< 24 hours for the inclusion and possibility to start treatment/surgery within 6 hours after randomisation)

- DWI infarct volume > 145 cm3

Exclusion criteria:

- The patients having a neurological pre existing handicap (score of Rankin sup or equal in 2).

- Patients having an ischaemia lateral against significant.

- Patients having a haemorrhagic transformation(conversion) sup in 50 % of the territory of the infarct.

- Patients having a severe co-morbidity with a reduced life expectation.

- Patients having a severe cardio-respiratory co-morbidity.

- Patients having antecedent of DUROPLASTIE with transplant of dura mater or transplant of cornea.

- Patients having a thrombolyses in 24 last hours.

- Patients having a severe coagulopathies.

- Patients having one against indication in the general anesthetic.

- Patients for whom a medical follow-up is not possible.

- The pregnant women.

- The patients to whom the surgical operation cannot be realized within 6 hours following the randomisation.

结果

主要结果指标

1. Primary endpoint: Functional outcome at 6 months [at 6 months]

次要成果指标

1. Secondary endpoints: [during the study]

2. Mortality [during the study]

3. Functional outcome at 9 and 12 months (mRS, NIHSS, Barthel-index) after stroke [at 9 and 12 months and after stroke]

4. Quality of life at 6 and 12 months (SIS) [at 6 and 12 months]

5. Complications related to surgery [during the study]

6. Infarct size at day 5-14 and week 12 and 48 [at day 5-14 and week 12 and 48]

7. Brainstem lesions on T2* after day 5-14 and week 12 and 48 [after day 5-14 and week 12 and 48]

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge